Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Jul 12, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a treatment option called MR-guided High-Dose-Rate brachytherapy for men who have experienced a recurrence of prostate cancer in the area where the prostate used to be, especially after they have already received radiation therapy. The goal is to see if this targeted treatment can help manage the cancer that has returned. To be eligible for the trial, participants must be men who have previously undergone radiation treatment, have a confirmed recurrence of cancer through tests like biopsies or advanced imaging scans, and have certain levels of prostate-specific antigen (PSA) in their blood.

If you or a family member are considering joining this trial, you should be aware that participants will receive this specialized treatment at a single medical center. It's important that candidates do not have distant spread of cancer or severe side effects from earlier treatments. The study is currently recruiting men aged 18 and older, and it aims to evaluate the safety and effectiveness of this approach to help improve outcomes for those dealing with recurrent prostate cancer.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients who received previous RT to the prostate bed +/- pelvic nodal regions
• • 2. Prostate-bed recurrence identified by biopsy and/or MRI and/or PSMA-PET scan
• • 3. At least two continuous PSA elevations post RT and PSA above 0.2 ng/dl
• • 4. With or without ADT PSA doubling time from nadir greater than 6 months
• • 5. ECOG 0-2
• • 6. Age greater than 18 years
• Exclusion Criteria:
• • 1. Radiological (e.g. PSMA PET, CT, MRI or bone scan) evidence of or distant metastases
• • 2. History of ≥G3 gastrointestinal (GI) and genitourinary (GU) toxicities following RT
• • 3. Any contraindications to MR and/or brachytherapy